TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 173 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 1.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $332,483 | +5.7% | 40,448 | -0.8% | 0.02% | 0.0% |
| Q1 2024 | $314,491 | -1.9% | 40,790 | +14.4% | 0.02% | -5.6% |
| Q4 2023 | $320,646 | -52.7% | 35,667 | -53.0% | 0.02% | -58.1% |
| Q3 2023 | $678,305 | +54338.6% | 75,873 | -6.4% | 0.04% | -41.9% |
| Q2 2023 | $1,246 | -30.7% | 81,103 | +1.5% | 0.07% | -32.7% |
| Q1 2023 | $1,798 | +13.3% | 79,940 | +5.9% | 0.11% | +12.2% |
| Q4 2022 | $1,587 | -99.9% | 75,466 | +70.3% | 0.10% | +36.1% |
| Q3 2022 | $1,092,000 | -1.6% | 44,314 | -3.2% | 0.07% | +4.3% |
| Q2 2022 | $1,110,000 | +4.1% | 45,800 | +10.7% | 0.07% | +21.1% |
| Q1 2022 | $1,066,000 | +37.2% | 41,378 | +65.3% | 0.06% | +50.0% |
| Q4 2021 | $777,000 | – | 25,039 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 1,026,300 | $21,583 | 6.98% |
| Deep Track Capital, LP | 4,582,000 | $96,359,460 | 4.05% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 379,019 | $7,963,189 | 2.46% |
| ARMISTICE CAPITAL, LLC | 6,412,000 | $134,844,360 | 2.35% |
| GREAT POINT PARTNERS LLC | 475,000 | $9,989,250 | 1.96% |
| RA Capital Management | 3,984,681 | $83,797,841 | 1.70% |
| MPM BioImpact LLC | 281,711 | $5,924,382 | 1.54% |
| HighVista Strategies LLC | 121,834 | $2,562,169 | 1.52% |
| Kynam Capital Management, LP | 418,099 | $8,792,622 | 1.35% |
| SECTORAL ASSET MANAGEMENT INC | 292,320 | $6,147,490 | 1.19% |